

ESASigte 12/30/03 4239-66335 243779  
E-08-199/0-US-10

PATENT  
Attorney Reference Number 4239-66335

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dong et al.

Application No. 10/627,952

Filed: July 24, 2003

Confirmation No. Not yet assigned

For: DIAGNOSTIC METHODS FOR GENE  
THERAPY USING REAGENTS DERIVED  
FROM THE HUMAN METASTASIS  
SUPPRESSOR GENE KAI1

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 4239-66335


COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent  
for Applicant(s)

Date Mailed December 30, 2003



TRANSMITTAL LETTER


Enclosed for filing in the application referenced above are the following:

- Information Disclosure Statement
  - Form 1449
- The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

  
Susan Alpert Siegel, Ph.D.  
Registration No. 43,121

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391 / Facsimile: (503) 228-9446

cc: Docketing



12/30/03 4239-66335 243727

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Dong et al.

**Application No.** 10/627,952

**Filed:** July 24, 2003

**Confirmation No.** Not yet assigned

**For:** DIAGNOSTIC METHODS FOR GENE  
THERAPY USING REAGENTS DERIVED  
FROM THE HUMAN METASTASIS  
SUPPRESSOR GENE KAI1

**Examiner:** Not yet assigned

**Art Unit:** Not yet assigned

**Attorney Reference No.** 4239-66335

**CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent  
for Applicant(s)

Date Mailed December 30, 2003

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**FOR CONTINUING APPLICATIONS**

Listed on the accompanying form PTO-1449 are several English-language documents.

Applicants respectfully request that such documents be listed as references cited on the issued patent.

The present application relies upon U.S. Patent Application No. 09/795,380, filed February 27, 2001, which is a divisional of U.S. Patent Application No. 09/232,507, filed January 15, 1999 (now abandoned), which is a divisional of U.S. Patent Application No. 08/430,225, filed April 28, 1995, which issued as U.S. Patent No. 6,204,000. Furthermore, documents listed on the accompanying form PTO-1449 were disclosed to or cited by the Patent Office in the earlier U.S. applications.

Copies of the documents listed on the accompanying form PTO-1449 that were cited by applicants in the earlier applications need not be sent to the Patent Office pursuant to 37 C.F.R. § 1.98. However, applicants will furnish the Patent Office with such copies upon request.


Please charge any additional fees that may be required in connection with filing this Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of the transmittal sheet for this Information Disclosure Statement is enclosed.

The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

  
Susan Alpert Siegel, Ph.D.  
Registration No. 43,121

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446



4239-66335 243723

**ON DISCLOSURE STATEMENT  
BY APPLICANT**

|                               |                  |
|-------------------------------|------------------|
| <b>Attorney Docket Number</b> | 4239-66335       |
| <b>Application Number</b>     | 10/627,952       |
| <b>Filing Date</b>            | July 24, 2003    |
| <b>First Named Inventor</b>   | Dong             |
| <b>Art Unit</b>               | Not yet assigned |
| <b>Examiner Name</b>          | Not yet assigned |

## U.S. PATENT DOCUMENTS

| Examiner's Initials* | Cite No. (optional) | Number    | Date          | Name        |
|----------------------|---------------------|-----------|---------------|-------------|
|                      |                     | 6,204,000 | 20 March 2001 | Dong et al. |

## **FOREIGN PATENT DOCUMENTS**

| <b>Examiner's Initials*</b> | <b>Cite No.<br/>(optional)</b> | <b>Number</b> | <b>Date</b> | <b>Country</b> |
|-----------------------------|--------------------------------|---------------|-------------|----------------|
|                             |                                |               |             |                |


**Examiner's Initials\***      **Cite No. (optional)**      **OTHER DOCUMENTS**

|  |  |  |
|--|--|--|
|  |  | Adachi et al., <i>Cancer Res.</i> , 56(8):1751-55, 1996.   |
|  |  | Crystal, <i>Science</i> , 270:404-410, 1995.   |
|  |  | Deonarain, <i>Exp. Opin. Ther. Patents</i> , 8(1):53-69, 1998.                                     |
|  |  | Dong et al., <i>Proc. of the Ameri. Assoc. for Cancer Res.</i> , 35:186 (Abstract No. 1111), 1994. |
|  |  | Dong et al., <i>Proc. of the Ameri. Assoc. for Cancer Res.</i> , 36:105 (Abstract No.630), 1995.   |
|  |  | Dong et al., <i>Proc. of the Ameri. Assoc. for Cancer Res.</i> , 35:692 (Abstract No.692), 1995.   |
|  |  | Dong et al., <i>Science</i> , 265(5112):884-86, 1995.  |
|  |  | Dong et al., <i>Cancer Res.</i> , 56:4387-4390, 1996.  |
|  |  | Dong et al., <i>Current Opin. in Oncology</i> , 9(1):101-7, 1997.                                  |
|  |  | Fukudome et al., <i>J. Virol.</i> , 66:1394-1401, 1992.  |
|  |  | Gaugitsch et al., <i>Eur. J. Immunol.</i> , 21:377-383, 1991.                                      |
|  |  | Gil et al., <i>J. Immunol.</i> , 148:2826-2833, 1992.  |

**EXAMINER  
SIGNATURE:** \_\_\_\_\_ **DATE  
CONSIDERED:** \_\_\_\_\_

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 8 2004


**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

|                               |                  |
|-------------------------------|------------------|
| <b>Attorney Docket Number</b> | 4239-66335       |
| <b>Application Number</b>     | 10/627,952       |
| <b>Filing Date</b>            | July 24, 2003    |
| <b>First Named Inventor</b>   | Dong             |
| <b>Art Unit</b>               | Not yet assigned |
| <b>Examiner Name</b>          | Not yet assigned |

|  |   |
|--|---|
|  | Ichikawa et al., <i>Cancer Res.</i> , 51:3788-3792, 1991.   |
|  | Ichikawa et al., <i>Cancer Res.</i> , 52:3489-3490, 1992.   |
|  | Imai et al., <i>J. Immunol.</i> , 149:2879-2886, 1992.  |
|  | Mashimo et al., <i>PNAS of USA</i> , 95(19):11307-11, 1998.   |
|  | Miller et al., <i>FASEB</i> , 9:190-199, 1995.  |
|  | Orkin et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," 1-20, 1995. |
|  | Rinker-Schaeffer et al., <i>Cancer Res.</i> , 54(23):6249-56, 1994.   |
|  | Verma et al., <i>Nature</i> , 389:239-242, 1997.  |
|  | Yang et al., <i>Cancer Letter</i> , 119(2):149-55, 1997.  |

|  |                     |
|--|---------------------|
| EXAMINER<br>SIGNATURE:   | DATE<br>CONSIDERED: |
| * Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant. |                     |